SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma rises on launching FluGuard in India at Rs 35 per tablet

05 Aug 2020 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 532.50, up by 4.00 points or 0.76% from its previous closing of Rs. 528.50 on the BSE.

The scrip opened at Rs. 536.35 and has touched a high and low of Rs. 537.70 and Rs. 530.30 respectively. So far 195543 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 540.75 on 31-Jul-2020 and a 52 week low of Rs. 315.20 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 540.75 and Rs. 487.65 respectively. The current market cap of the company is Rs. 128004.52 crore.

The promoters holding in the company stood at 54.69%, while Institutions and Non-Institutions held 32.81% and 12.50% respectively.

Sun Pharmaceutical Industries has launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

The company will work closely with the government and medical community to ensure availability of FluGuard to patients across the country. The stocks of FluGuard will be available in the market from this week.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma. Inds. Share Price

1862.70 -9.90 (-0.53%)
30-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.70
Dr. Reddys Labs. 1356.85
Cipla 1465.15
Zydus Lifesciences 1112.20
Lupin 2420.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: